This article is intended for primary care physicians, geriatricians, endocrinologists, and other specialists who care for patients with vitamin B12 deficiency.
The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months," that could create a conflict of interest.
Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 5/27/2005; Reviewed and Renewed: 5/26/2006
Valid for credit through: 5/26/2007, 11:59 PM EST
processing....
May 27, 2005 -- In adults older than age 70 years, a dose more than 200 times the recommended dietary allowance (RDA) of B 12 is necessary to normalize mild deficiency, according to the results of a randomized study published in the May 23 issue of the Archives of Internal Medicine.
"Supplementation with high doses of oral cobalamin is as effective as cobalamin administered by intramuscular injection to correct plasma markers of vitamin B 12 deficiency, but the effects of lower oral doses of cobalamin on such markers are uncertain," write Simone J.P.M. Eussen, MSc, from Wageningen University in the Netherlands, and colleagues.
In this parallel-group, double-blind, dose-finding trial, the investigators assessed the effects of daily oral doses of 2.5, 100, 250, 500, and 1,000 µg of cyanocobalamin administered for 16 weeks on biochemical markers of vitamin B 12 deficiency in 120 older people. Study subjects had mild vitamin B 12 deficiency, defined as a serum vitamin B 12 level of 100 to 300 pmol/L (135 - 406 pg/mL) and a methylmalonic acid level of at least 0.26 µmol/L. The primary outcome was the dose of oral cyanocobalamin that produced 80% to 90% of the estimated maximal reduction in the plasma methylmalonic acid concentration.
Supplementation with cyanocobalamin at daily oral doses of 2.5, 100, 250, 500, and 1,000 µg was associated with mean reductions in plasma methylmalonic acid concentrations of 16%, 16%, 23%, 33%, and 33%, respectively. To achieve 80% to 90% of the estimated maximum reduction in the plasma methylmalonic acid concentration, daily doses of 647 to 1,032 µg of cyanocobalamin were required.
Study limitations include the variable absorption of vitamin B 12 in older people, current assay techniques that may misclassify a significant proportion of individuals with vitamin B 12 deficiency, lack of consensus about the cutoff points for vitamin B 12 deficiency or metabolites to define vitamin B 12 deficiency, and the extent to which differences in individual responses were due to active vs passive absorption of vitamin B 12.
"The lowest dose of oral cyanocobalamin required to normalize mild vitamin B 12 deficiency is more than 200 times greater than the recommended dietary allowance, which is approximately 3 µg daily," the authors write. "Clinical trials are currently assessing the effects of high doses of oral cobalamin on markers of cognitive function and depression. If such trials can demonstrate that the reported associations of vitamin B 12 deficiency with cognitive impairment or depression are causal and reversible by treatment, the relevance of correction of vitamin B 12 deficiency in older people could be substantial."
ZonMw in the Hague, Kellogg's Benelux, the Foundation to Promote Research Into Functional Vitamin B 12 Deficiency, and the European Union BIOMED Demonstration Project supported this study.
The authors report no financial disclosures.
Arch Intern Med. 2005;165:1167-1172